Vascularization Pattern of C6 Glioma is Modified with Medroxyprogesterone Acetate and Ibuprofen in Wistar Rat Brain

Meric A ALTINOZ1, Engin OZAR3, Murat TASKIN3, Evin BOZCALI1, Ayhan BILIR1, Tuncay ALTUG2, Adnan AYDINER2, Aydin SAV4

1Department of Histology and Embryology, Faculty of Medicine, Istanbul University, Bakirkoy/Istanbul, Turkey
2Institute of Oncology, Faculty of Medicine, Istanbul University, Istanbul, Turkey
31 st Neurosurgery Clinic, Bakirkoy Mental Diseases Hospital, Bakirkoy, Turkey
4Talia Bali Aykan Neuropathology Laboratory, Institute of Neuroscience, Marmara University, Bakirkoy/Istanbul, Turkey


Beneficial effects of medroxyprogesterone acetate (MPA) in cancer therapy is partly mediated via its antiangiogenic activity. The same is true for the antitumoral action of non-steroidal antiinflammatory drugs. We have studied two liposoluble drugs, MPA and the analgesic ibuprofen, on glioma vascularization in vivo. In this study we have shown that, until the sacrifice at 27. day after tumor inoculation in the right hemisphere, MPA had a slight though insignificant activity to reduce the fatality of C6 glioma, growing in right cerebral hemisphere of male Wistar rats. But ibuprofen both alone or with MPA had no effect on survival with gavage application of a 30 mg/kg/day dosing regime. On histological analysis, intra- and peritumoral vessels were counted. Progesterone seemed to lower intratumoral, but to increase peritumoral vessels, especially glomeruloids, around the tumor mass. Coadministration of ibuprofen acted to suppress the peritumoral vessel increase, and to enhance lymphomonocytic infiltration around tumor vessels. Pathology & Oncology Research, Vol 7, Nr 3, 185-189, 2001

Key words: medroxyprogesterone; ibaprofen; glioma; angiogenesis

Received: Apr 27, 2001; accepted: Sep 10, 2001
Correspondence: Meric A ALTINOZ, Talia Bali Aykan Neuropathology Laboratory, Institute of Neuroscience, Marmara University, General Sukru Kanatli Sok. No: 36/8 Bakirkoy/Istanbul , Turkey; Tel: 90–212-570 7743, Fax: 90-212-511 7871; E-mail:

Click here to get the full-text version in PDF!